CR7658A - COMPOSITION INCLUDING A CHOLESTEROL ABSORPTION INHIBITOR A HMG-COA INHIBITOR AND A STABILIZING AGENT - Google Patents

COMPOSITION INCLUDING A CHOLESTEROL ABSORPTION INHIBITOR A HMG-COA INHIBITOR AND A STABILIZING AGENT

Info

Publication number
CR7658A
CR7658A CR7658A CR7658A CR7658A CR 7658 A CR7658 A CR 7658A CR 7658 A CR7658 A CR 7658A CR 7658 A CR7658 A CR 7658A CR 7658 A CR7658 A CR 7658A
Authority
CR
Costa Rica
Prior art keywords
inhibitor
hmg
cholesterol absorption
stabilizing agent
composition including
Prior art date
Application number
CR7658A
Other languages
Spanish (es)
Inventor
William D Moore
Shaun Fitzpatrick
Christian Seiler
Robert Saklatvala
Catherine R Petts
Wing-Kee Philip Cho
Original Assignee
Schering Corp
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40091458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR7658(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp, Merck Sharp & Dohme filed Critical Schering Corp
Priority to CR7658A priority Critical patent/CR7658A/en
Publication of CR7658A publication Critical patent/CR7658A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion proporciona una composicion farmaceutica que comprende un inhibidor de la absorcion de colesterol y un inhibidor de una HMG-CoA reductasa, con uno o mas antioxidantes, celuosa microcristalina, hidroxipropil metilcelulosa, estearato de magnesio y lactosa. La composicion no necesita contener acido ascorbico en orden de obtener la estabilidad deseable.The present invention provides a pharmaceutical composition comprising a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor, with one or more antioxidants, microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate and lactose. The composition does not need to contain ascorbic acid in order to obtain desirable stability.

CR7658A 2005-01-19 2005-01-19 COMPOSITION INCLUDING A CHOLESTEROL ABSORPTION INHIBITOR A HMG-COA INHIBITOR AND A STABILIZING AGENT CR7658A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CR7658A CR7658A (en) 2005-01-19 2005-01-19 COMPOSITION INCLUDING A CHOLESTEROL ABSORPTION INHIBITOR A HMG-COA INHIBITOR AND A STABILIZING AGENT

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CR7658A CR7658A (en) 2005-01-19 2005-01-19 COMPOSITION INCLUDING A CHOLESTEROL ABSORPTION INHIBITOR A HMG-COA INHIBITOR AND A STABILIZING AGENT

Publications (1)

Publication Number Publication Date
CR7658A true CR7658A (en) 2007-02-05

Family

ID=40091458

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7658A CR7658A (en) 2005-01-19 2005-01-19 COMPOSITION INCLUDING A CHOLESTEROL ABSORPTION INHIBITOR A HMG-COA INHIBITOR AND A STABILIZING AGENT

Country Status (1)

Country Link
CR (1) CR7658A (en)

Similar Documents

Publication Publication Date Title
ECSP055573A (en) COMPOSITION INCLUDING A CHOLESTEROL ABSORPTION INHIBITOR, A HMG-CoA REDUCTASA INHIBITOR AND A STABILIZING AGENT
GEP20105083B (en) A solid pharmaceutical dosage formulation
GT200800123A (en) MODIFIED LISINE MIMETIC COMPOUNDS
CR10528A (en) PROCESS TO PRODUCE POXVIRUS AND POXVIRUS COMPOSITIONS
CL2012003625A1 (en) An aqueous composition containing bromhexine, wherein the composition has an amount of sugar-alcohols less than 10 g based on 100 ml of the composition; and its use for secretory therapy in acute and chronic bronchopulmonary diseases.
HN2008000278A (en) ASSOCIATION OF A LONG ACTION HYPNOTIC AGENT AND A SHORT ACTION DURATION HYPNOTIC AGENT AND ITS THERAPEUTIC APPLICATION
CA130203S (en) Display screen
CA130204S (en) Display screen
DE602007010664D1 (en) P53 ACTIVATING BENZOYL HYDROGEN AND BENZOYLTHINE OXYGEN COMPOUNDS
TW200707266A (en) Adjustable mouse
CA128932S (en) Display screen
CA128931S (en) Display screen
ECSP088476A (en) COMBINATION OF FUNGICIDE ACTIVE PRODUCTS
AR048672A1 (en) DISINTEGRATION TABLETS THAT INCLUDE LICARBAZEPINA
CL2009000665A1 (en) Pyrrolidinyl derived compounds; pharmaceutical composition comprising said compounds; and its use in the treatment of anxiety, depression or both.
CA130205S (en) Display screen
DK1994926T3 (en) Valsartan formulations
AR063152A1 (en) COMBINED PHARMACO
EA201071412A1 (en) DRONEDARON FOR THE PREVENTION OF CARDIUM VERSION
ATE410154T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING 2,4-DICHLOROBENZYL ALCOHOL AND AMYLMETACRESOL
CR7658A (en) COMPOSITION INCLUDING A CHOLESTEROL ABSORPTION INHIBITOR A HMG-COA INHIBITOR AND A STABILIZING AGENT
ES2561813T3 (en) Topical application of nimesulide and thiocolchicose
PE20060157A1 (en) NATURAL COMPOSITION INCLUDING MONASCUS FUNGUS AND GRAPE EXTRACT
DOP2003000676A (en) PHARMACEUTICAL FORMULATION
PA8795401A1 (en) ASSOCIATION BETWEEN AN ANTIATEROTROMBOTIC AND AN INHIBITOR OF THE ANGIOTENSIN CONVERSION ENZYME